60875-16-3

Usage

Uses

Used in Pharmaceutical Industry:
4-(3-Methyl-5-oxo-2-pyrazolin-1-yl)benzoic acid is used as a modulator for p300/cbp activity for its potential role in the development of novel therapeutics. The modulation of p300/cbp activity can have implications in various disease conditions, making 4-(3-Methyl-5-oxo-2-pyrazolin-1-yl)benzoic acid a valuable candidate for further research and development in the pharmaceutical sector.
Used in Chemical Research:
As a compound with specific pharmacological properties, 4-(3-Methyl-5-oxo-2-pyrazolin-1-yl)benzoic acid is used as a research tool in chemical and biological studies. It can help scientists understand the mechanisms of p300/cbp activity and its role in cellular processes, which may lead to the discovery of new drugs or therapies.
Used in Drug Development:
4-(3-Methyl-5-oxo-2-pyrazolin-1-yl)benzoic acid is used as a lead compound in drug development. Its ability to modulate p300/cbp activity suggests that it could be a starting point for creating new drugs targeting this pathway, which may have applications in treating various diseases and conditions.

InChI:InChI=1/C11H10N2O3/c1-7-6-10(14)13(12-7)9-4-2-8(3-5-9)11(15)16/h2-5H,6H2,1H3,(H,15,16)/p-1

Upstream product

• 141-97-9 ethyl acetoacetate 
• 619-67-0 4-Hydrazinobenzoic acid 
• 105-45-3 acetoacetic acid methyl ester 
• 5326-27-2 2-hydrazino-benzoic acid 
• 150-13-0 4-amino-benzoic acid 
• 24589-77-3 4-hydrazinobenzoic acid hydrochloride 

Downstream Products

• 948853-49-4 4-(2,3-dimethyl-5-oxo-2,5-dihydro-pyrazol-1-yl)-benzoic acid 
• 1061212-69-8 1-(4-carboxyphenyl)-2,3-dimethyl-5-pyrazolone methyl ester 
• 265118-48-7 N-(3-aminopropyl)-4-(3-methyl-5-oxo-2-pyrazolin-1-yl)benzamide 
• 107430-43-3 1-(4-hydroxymethylphenyl)-3-methyl-2-pyrazolin-5-one 
• 107430-36-4 ethyl 4-(3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoate 
• 1093127-81-1 C₂₂H₁₆N₂O₄ 
• 1270120-43-8 C₂₆H₂₂N₂O₆ 
• 1270120-48-3 C₂₅H₁₉N₃O₄ 
• 1270120-46-1 C₂₇H₂₄N₂O₆ 
• 1270120-39-2 C₂₅H₂₂N₂O₅ 
• 1423013-76-6 4-{4-[(1H-indol-3-yl)methylene]-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl}benzoic acid 
• 1423013-77-7 4-{3-methyl-4-[(1-methyl-1H-indol-3-yl)methylene]-5-oxo-4,5-dihydro-1H-pyrazol-1-yl}benzoic acid 

Relevant academic research and scientific papers

Discovery of novel inhibitors of human phosphoglycerate dehydrogenase by activity-directed combinatorial chemical synthesis strategy

Serine, the source of the one-carbon units essential for de novo purine and deoxythymidine synthesis plays a crucial role in the growth of cancer cells. Phosphoglycerate dehydrogenase (PHGDH) which catalyzes the first, rate-limiting step in de novo serine biosynthesis has become a promising target for the cancer treatment. Here we identified H-G6 as a potential PHGDH inhibitor from the screening of an in-house small molecule library based on the enzymatic assay. We adopted activity-directed combinatorial chemical synthesis strategy to optimize this hit compound. Compound b36 was found to be the noncompetitive and the most promising one with IC50 values of 5.96 ± 0.61 μM against PHGDH. Compound b36 inhibited the proliferation of human breast cancer and ovarian cancer cells, reduced intracellular serine synthesis, damaged DNA synthesis, and induced cell cycle arrest. Collectively, our results suggest that b36 is a novel PHGDH inhibitor, which could be a promising modulator to reprogram the serine synthesis pathway and might be a potential anticancer lead worth further exploration.

XPA INHIBITOR COMPOUNDS AND THEIR USE

The present disclosure relates to certain compounds having binding affinity for XPA, and uses thereof. Specifically, the present disclosure relates to the use of XPA inhibitors as described herein in in methods of treating cancer.

Efficient Synthesis of Five Types of Heterocyclic Compounds via Intramolecular Elimination Using Ultrasound-Static Heating Technique

An experimental technique, ultrasound-static heating, has been developed for the efficient synthesis of heterocyclic compounds. The technique involves ultrasonic irradiation and static heating processes. First, the ultrasonic irradiation process is performed to form an intermediate of the heterocyclic compound under mild conditions and the subsequent static heating process (heating the intermediate under solvent-free conditions without stirring) produces the target heterocyclic compounds via intramolecular elimination.

Design and Structure-Guided Development of Novel Inhibitors of the Xeroderma Pigmentosum Group A (XPA) Protein-DNA Interaction

XPA is a unique and essential protein required for the nucleotide excision DNA repair pathway and represents a therapeutic target in oncology. Herein, we are the first to develop novel inhibitors of the XPA-DNA interaction through structure-guided drug design efforts. Ester derivatives of the compounds 1 (X80), 22, and 24 displayed excellent inhibitory activity (IC50 of 0.82 ± 0.18 μM and 1.3 ± 0.22 μM, respectively) but poor solubility. We have synthesized novel amide derivatives that retain potency and have much improved solubility. Furthermore, compound 1 analogs exhibited good specificity for XPA over RPA (replication protein A), another DNA-binding protein that participates in the nucleotide excision repair (NER) pathway. Importantly, there were no significant interactions observed by the X80 class of compounds directly with DNA. Molecular docking studies revealed a mechanistic model for the interaction, and these studies could serve as the basis for continued analysis of structure-activity relationships and drug development efforts of this novel target.

KU INHIBITORS AND THEIR USE

The present disclosure relates to certain compounds having binding affinity for Ku, and uses thereof. Specifically, the present disclosure relates to the use of Ku inhibitors as described herein in site-specific genome engineering technologies, including but not limited to CRISPR/Cas9, Zinc finger nuclease (ZFN), Transcription activator-like effector nuclease (TALEN), and meganuclease. The present disclosure also relates to kits useful for site-specific genome engineering that include at least one compound as described herein.

Viable and straightforward approach to the preparation of water soluble pyrazol-5-one derivatives through glycoconjugation

The synthesis of water soluble pyrazol-5-one azo-dyes has been achieved. 6′-Aminolactosetriacetonide 9 was selected as the key building block to glyconjugate the pyrazole ring at its 3 position via a carboxamide or via a benzeneamide moiety in position 1 of the heterocycle. Diethyl-3-oxopentandionate 2 led eventually to a bicyclic compound, hampering the glyconjugation coupling process. The values of the molar extinction coefficients (ε) confirmed the tendency of pyrazolone azo dyes to exist in their tautomeric hydrazo form (especially in polar solvents); whereas the presence of substituents on the phenylazo group influenced the visible absorption maxima negligibly.

Synthesis, crystal structure and evaluation of cancer inhibitory activity of 4-[indol-3-yl-methylene]-1H-pyrazol-5(4H)-one derivatives

A series of 4-(1H-indol-3-yl-methylene)-1H-pyrazol-5(4H)-one derivatives have been synthesised. The Z structure of 4-[(1-methyl-1H-indol-3-yl)methylene]- 3-phenyl-1-p-tolyl-1H-pyrazol-5-one was determined by X-ray crystallography. The antitumour activity was evaluated against five cancer cells by MTT assay. [(1H-Indol-3-yl)methylene]-1-(2,4-dinitrophenyl)- 3-methyl-1H-pyrazole-5-one and 4-{4-[(1-benzyl-1H-indol-3-yl)methylene]-3-methyl-5-oxo-4,5-dihydro-1Hpyrazol- 1-yl}-benzoic acid have similar anticancer activity with 5-UF on the test cancer cells (exception of A375). Almost all the target compounds displayed antitumour activity against A549 and PC-9, and those with benzyl at 1- position of indole had higher activity against PC-9 (IC50 value lower than 30 μM). Those with benzyl at the indole and carboxyl at the phenyl part of of pyrazole were more active against PC-9 and A549 cells, providing a good indication for subsequent optimisation as lung cancer inhibitory agents.

Virtual ligand screening of the p300/CBP histone acetyltransferase: Identification of a selective small molecule inhibitor

The histone acetyltransferase (HAT) p300/CBP is a transcriptional coactivator implicated in many gene regulatory pathways and protein acetylation events. Although p300 inhibitors have been reported, a potent, selective, and readily available active-sitedirected small molecule inhibitor is not yet known. Here we use a structure-based, in silico screening approach to identify a commercially available pyrazolone- containing small molecule p300 HAT inhibitor, C646. C646 is a competitive p300 inhibitor with a Ki of 400 nM and is selective versus other acetyltransferases. Studies on site-directed p300 HAT mutants and synthetic modifications of C646 confirm the importance of predicted interactions in conferring potency. Inhibition of histone acetylation and cell growth by C646 in cells validate its utility as a pharmacologic probe and suggest that p300/CBP HAT is a worthy anticancer target.

Methods and Compositions for Modulating P300/CBP Activity

The present invention relates to a method for identifying compounds that modulate the activity of p300/CBP. Compounds of the invention are identified by designing or screening for a compound which binds to at least one amino acid residue of the newly identified lysine-CoA inhibitor binding site, L1 loop, electronegative pocket, or electronegative groove of the HAT domain of p300/CBP and testing the compound for its ability to modulate the activity of p300/CBP. Compositions and methods for preventing or treating diseases or disorders associated with p300/CBP are also provided as is a method for producing a semi-synthetic HAT domain.

OXIDATIVE COLOR-DEVELOPING COMPOUNDS, SALTS THEREOF, PROCESS FOR PRODUCTION OF THE SAME, REAGENT COMPOSITIONS AND TEST TOOLS MADE BY USING THE SAME

It is an object of the present invention to provide a means for measuring a concentration of various components rapidly with high accuracy and high sensitivity. The present invention is to provide an oxidative chromogenic compound or salt thereof represented by the following chemical formula (1): wherein R1 and R2 are each independently a linear or branched alkyl group having 1 to 5 carbon atoms; R3, R4, R5, R6 and R7 are each independently a hydrogen atom, a carboxyl group or a sulfonic acid group, or salt thereof, provided that at least one of R3 to R7 is a carboxyl group or a sulfonic acid group, or salt thereof, and the others are hydrogen atoms, and the production method thereof, and the reagent composition and test instrument using the same.